Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine

Drug Metabolism and Disposition

Volumn 24, Issue 4, 1996, Pages 487-494

  Sharer, Jane E ^a,b   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; PHENAZONE;

AEROBIC METABOLISM; ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STABILITY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIPYRINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES; REGRESSION ANALYSIS;

EID: 0029875703     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. M. Hartleb: Drugs and the liver. Part II. The role of the antipyrine test in drug metabolism studies. Biopharm. Drug Dispos. 12, 559-570 (1991).
2. H. E. Poulsen and S. Loft: Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J. Hepatol. 6, 374-382 (1988).
3. S. A. Wrighton, M. VandenBranden, J. C. Stevens, L. A. Shipley, and B. J. Ring: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25, 453-484 (1993).
4. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).
5. J. O. Miners, M. E. Veronese, and D. J. Birkett: In vitro approaches for the prediction of human drug metabolism. Ann. Rep. Med. Chem. 29, 307-316 (1994).
6. B. J. Ring, J. Catlow, T. J. Lindsay, T. Gillespie, L. K. Roskos, B. J. Cerimile, S. P. Swanson, M. A. Hamman, and S. A. Wrighton: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 276, 658-666 (1996).
7. J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
8. T. A. van der Hoeven and M. J. Coon: Preparation and properties of partially purified cytochrome P-450 and reduced nicotrinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249, 6302-6310 (1974).
9. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
10. B. B. Brodie and J. Axelrod: The fate of antipyrine in man. J. Pharmacol. Exp. Ther. 98, 97-104 (1950).
11. P. B. Andreasen and E. S. Vesell: Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin. Pharmacol. 16, 1059-1065 (1974).
12. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
13. A. R. Boobis, M. J. Brodie, G. C. Kahn, E. L. Toverud, I. A. Blair, S. Murray, and D. S. Davies: Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br. J. Clin. Pharmacol. 12, 771-777 (1981).
14. G. Engel, U. Hofrnann, and M. Eichelbaum: Highly sensitive and specific gas chromatographic-tandem mass spectrometric method for the determination of trace amounts of antipyrine metabolites in biological material. J. Chromatogr. 666, 111-116 (1995).
15. 14C]coumarin by human liver microsomes. Xenobiotica 24, 795-803 (1994).
16. S. E. Clarke, A. D. Ayrton, and R. J. Chenery: Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24, 517-526 (1994).
17. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandoraycin, α-naphthoflavone, and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
18. R. E. Vestal, A. H. Norris, J. D. Tobin, B. H. Cohen, N. W. Shock, and R. Andres: Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin. Pharmacol Ther. 18, 425-432 (1975).
19. K. Vahakangas, O. Pelkonen, and E. Sotaniemi: Cigarette smoking and drug metabolism. Clin. Pharmacol. Ther. 33, 375-380 (1983).
20. A. Kappas, A. P. Alvares, K. E. Anderson, E. J. Pantuck, C. B. Pantuck, R. Chang, and A. H. Conney: Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin. Pharmacol. Ther. 23, 445-450 (1978).
21. E. J. Pantuck, C. B. Pantuck, W. A. Garland, B. H. Min, L. W. Wattenberg, K. E. Anderson, A. Kappas, and A. H. Conney: Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin. Pharmacol. Ther. 25, 88-95 (1979).
22. E.-L. Toverud, A. R. Boobis, M. J. Brodie, S. Murray, P. N. Bennett, V. Whitmarsh, and D. S. Davies: Differential induction of antipyrine metabolism by rifampicin. Eur. J. Clin. Pharmacol. 21, 155-160 (1981).
23. E. E. Ohnhaus, N. Brockmeyer, P. Dylewicz, and H. Habicht: The effect of antipyrine and rifampicin on the metabolism of diazepam. Clin. Pharmacol. Ther. 42, 148-156 (1987).
24. E. Perucca, R. Grimaldi, G. M. Frigo, A. Sardi, H. Mönig, and E. E. Ohnhaus: Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol. 34, 595-599 (1988).
25. S. M. Borcherding, T. L. Bastian, T. H. Self, N. Abou-Shala, B. W. LeDuc, and R L. Lalonde: Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism. Antimicrob. Agents Chemother. 36, 1553-1558 (1992).
26. M. Danhof, R. M. A. Verbeek, C. J. van Boxtel, J. K. Boeijinga, and D. D. Breimer: Differential effects of enzyme induction on antipyrine metabolite formation. Br. J. Clin. Pharmacol. 13, 379-386 (1982).
27. F. P. Guengerich: Human cytochrome P450 enzymes. In "Cytochrome P450" (O. de Montellano, ed.), 2nd ed. Plenum Press. New York, 1995.
28. K. A. Bachmann and L. Jauregui: Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica, 23, 307-315 (1993).
29. H. Wietholtz, T. Zysset, H.-U. Marschall, K. Generet, and S. Matem: The influence of rifampin treatment on caffeine clearance in healthy man. J. Hepatol. 22, 78-81 (1995).
30. M. A. Sarkar, C. Hunt, P. S. Guzelian, and H. T. Karnes: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab. Dispos. 20, 31-37 (1992).
31. Z.-Y. Zhang and L. S. Kaminsky: Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50, 205-211 (1995).
32. C. L. Denlinger, K. K Stryker, L. B. Slusher, and E. S. Vesell: Studies on theophylline metabolism: autoinduction and inhibition by antipyrine. Clin. Pharmacol. Ther. 41, 522-530 (1987).
33. Y. Masubuchi, S. Hosokawa, T. Horie, T. Suzuki, S. Ohmori, M. Kitada, and S. Narimatsu Cytochrome P450 Isozymes involved in propranolol metabolism in human liver microsomes. Drug Metab. Dispos. 22, 909-915 (1994).
34. K. Yoshimoto, H. Echizen, K. Chiba, M. Tani, and T. Ishizaki: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39, 421-431 (1995).
35. N. D. S. Bax, M S. Lennard, and G. T Tucker: Inhibition of antipyrine metabolism by β-adrenoceptor antagonists. Br. J. Clin. Pharmacol. 12, 779-784 (1981).
36. H. K. Kroemer, J. Gautier, P. Beaune, C. Henderson, C. R. Wolf, and M. Eichelbaum: Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol. 348, 332-337 (1993).
37. L. Pichard, G. Gillet, I. Fabre, I. Dalet-Beluche, C. Bonfils, J. P. Thenot, and P. Maurel: Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug. Metab. Dispos. 18, 711-719 (1990).
38. L. A. Bauer, M. Stenwall, J. R. Horn, R. Davis, K. Opheim, and L. Greene: Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin. Pharmacol. Ther. 40, 239-242 (1986).
39. D. Bach, R. Blevins, N. Kemer, M. Rubenfire, and D. J. Edwards: The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. Br. J. Clin. Pharmacol. 21, 655-659 (1986).
40. H. Sakai, S. Kobayashi, K. Hamada, S. Iida, H. Akita, E. Tanaka, E. Uchida, and H. Yasuhara: The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates. Br. J. Clin. Pharmacol. 31, 353-355 (1991).
41. G. Carrum, J. M. Egan, and D. R. Abemathy: Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine. Clin. Pharmacol. Ther. 40, 140-143 (1986).
42. M. B. Bottorff, R. L. Lalonde, D. J. Kazierad, T. J. Boon, S. J. Tsiu, and D. M. Mirvis: The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. Pharmacotherapy 9, 315-321 (1989).
43. P. Periti, T. Mazzei, E. Mini, and A. Novelli: Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23, 106-131 (1992).
44. D. Passayre, D. Larrey, J. Vitaux, P. Breil, J. Belghiti, and J.-P. Benhamou: Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Pharmacol. 31, 1699-1704 (1982).
45. D. Larrey, C. Funck-Brentano, P. Breil, J. Vitaux, C. Theodore, G. Babany, and D. Passayre: Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem. Pharmacol. 32, 1063-1068 (1983).
46. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulfaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
47. G. T. Blyden, D. R. Abernathy, and D. J. Greenblatt: Ketoconazole does not impair antipyrine clearance in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 24, 225-226 (1986).
48. T. K. Daneshmend, D. W. Warnock, M. D. Ene, E. M. Johnson, G. Parker. M. E. Richardson, and C. J. C. Roberts: Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J. Antimicrob. Chemother. 12, 185-188 (1983).
49. A. P. D'Mello, M. J. D'Souza, and T. R. Bates: Pharmacokinetics of ketoconazole-antipyrine interaction. Lancet 2, 209-210 (1985).
50. C. Brass, J. N. Galgiani, T. F. Blaschke, R. Defelice, R. A. O'Reilly, and D. A. Stevens: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chemother. 21, 151-158 (1982).
51. Y. Horsmans, J. P. Desager, S. Pauwels, and C. Harvengt: Lack of effect by nifedipine on hepatic mixed function oxidase in man. Fundam. Clin. Pharmacol. 5, 193-201 (1991).
52. G. I. Adebayo and A. F. B. Mabadeje: Effect of nifedipine on antipyrine and theophylline disposition. Biopharm. Drug Dispos. 11, 157-164 (1990).
53. T. H. Dickinson, J. M. Egan, and D. R. Abernethy: Effects of nifedipine on hepatic drug oxidation. Pharmacology 36, 405-410 (1988).
54. M. Nakano and T. Inaba: A radiometric assay for debrisoquine 4-hydroxylase in human liver microsomes. Can. J. Physiol. Pharmacol. 62, 84-88 (1984).
55. S. V. Otton, T. Inaba, W. A. Mahon, and W. Kalow: In vitro metabolism of sparteine by human liven competitive inhibition by debrisoquine. Can. J. Physiol. Pharmacol. 60, 102-105 (1982).
56. S. K. Bowles, L. Cardozo, and D. J. Edwards: Quinidine does not alter antipyrine metabolism. J. Clin. Pharmacol. 30, 267-271 (1990).
57. D. J. Back, J. Tjia, H. Monig, E. E. Ohnhaus, and B. K. Park: Selective inhibition of drug oxidation of two probe drugs, antipyrine and tolbutamide. Eur. J. Clin. Pharmacol. 34, 157-163 (1988).
58. D. B. Back, B. K. Park, J. F. Tjia, and S. N. Newby: Sulphaphenazole and drug oxidation in man. Br. J. Clin. Pharmacol. 16, 460-461 (1983).
59. T. D. Leemann, C. Transon, P. Bonnabry, and P. Dayer: A major role for cytochrome P450-TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp. Clin. Res. 19, 189-195 (1993).
60. L. J. Battellino, S. T. D. de Cattoni, and C. Ragagnin: Impairment of human antipyrine metabolism by piroxicam. Can. J. Physiol. Pharmacol. 68, 711-717 (1990).